International Journal of General Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2026-06-03 冲冲冲h 来自广东省

偏重的研究方向：真实世界;临床
经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？

5 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2023-11-23 ms3000001126828781 来自广西

审稿速度:2.0
偏重的研究方向：肿瘤学
经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。

178 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2026-02-25 匿名用户

A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal.

40 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2025-07-08 匿名用户

不接收case reports

78 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2024-04-22 呆子550 来自内蒙古

18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？

150 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2023-12-24 1251953cm97(暂无昵称) 来自北京

1A1状态5天了，什么时候能有变化呀

198 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2024-11-26 gzhjjx 来自贵州省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;放疗
经验分享：17 August 2024 Peer review selection
17 September 2024 First peer reviewer allocated
27 September 2024 First report returned
30 September 2024 Second or more peer reviewer reports returned
11 October 2024 Report sent to the Editor-in-Chief
26 October 2024 Report: revise with changes
31 October 2024 Resubmission pending
13 November 2024 Resubmitted manuscript received
22 November 2024 Processing revised manuscript
22 November 2024 Peer reviewer(s) second round
......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。

140 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2024-05-15 ms9000001639670421 来自江西省

偏重的研究方向：临床研究
经验分享：3月26号投的现在还在1A2，大家进度都咋样了？

185 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2024-06-20 烂医生来自江苏省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤学
经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了

159 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2320759, encodeId=47662320e5911, content=偏重的研究方向：真实世界;临床 经验分享：4c已经快20天了，一直没动静，没4cx，也没4cr，就是一直4c不动，有没有战友和我一样呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/30/1326c8f87cd23d5cadb97642c4d850bc.jpg, createdBy=b47b2366269, createdName=冲冲冲h, createdTime=Wed Jun 03 09:04:05 CST 2026, time=2026-06-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170615, encodeId=9ea521e0615c6, content=审稿速度:2.0 偏重的研究方向：肿瘤学 经验分享：生信文章，投稿两个月不到就接收了，审稿过程很快，过程的变化都会有邮件提醒，2680美元。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Thu Nov 23 22:26:53 CST 2023, time=2023-11-23, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2301529, encodeId=4cd9230152989, content=A Bibliometric Analysis：期刊不收bib， On behalf of the Editor-in-Chief, I regret to inform you that your manuscript is not suitable for International Journal of General Medicine as this study type is not accepted for this journal., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Feb 25 13:43:12 CST 2026, time=2026-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2272515, encodeId=147822e2515db, content=不接收case reports, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue Jul 08 14:49:04 CST 2025, time=2025-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2199793, encodeId=3b752199e939f, content=18号投的，目前1A_1 - INITIAL ASSESSMENT IN PROGRESS，大家投稿状态多久才变？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2361732147, createdName=呆子550, createdTime=Mon Apr 22 16:25:49 CST 2024, time=2024-04-22, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2176797, encodeId=f3fd21e6797fe, content=1A1状态5天了，什么时候能有变化呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=45e52538960, createdName=1251953cm97(暂无昵称), createdTime=Sun Dec 24 08:01:07 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2239326, encodeId=5fb7223932682, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;放疗 经验分享：17 August 2024 Peer review selection 17 September 2024 First peer reviewer allocated 27 September 2024 First report returned 30 September 2024 Second or more peer reviewer reports returned 11 October 2024 Report sent to the Editor-in-Chief 26 October 2024 Report: revise with changes 31 October 2024 Resubmission pending 13 November 2024 Resubmitted manuscript received 22 November 2024 Processing revised manuscript 22 November 2024 Peer reviewer(s) second round ......审稿一个月，给了3周小修，返回去没几天就Accept。口碑OK，非预警，审稿人非常专业和谨慎，提问细致且内行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Tue Nov 26 15:32:47 CST 2024, time=2024-11-26, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2204834, encodeId=958f22048341c, content=偏重的研究方向：临床研究 经验分享：3月26号投的现在还在1A2，大家进度都咋样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0859239868, createdName=ms9000001639670421, createdTime=Wed May 15 14:40:55 CST 2024, time=2024-05-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2210737, encodeId=0a0d2210e3795, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤学 经验分享：大家别投了，一审56天，编辑给我发消息了，我投了1个月还是1A1，想换杂志了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/c8f4595dadea4266aa1532bb03641b54/0826761e11894dafafe181f2cae69424.jpg, createdBy=1b7c5246256, createdName=烂医生, createdTime=Thu Jun 20 00:28:44 CST 2024, time=2024-06-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2144927, encodeId=d2e2214492ea2, content=请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7105612032, createdName=ms6000001074362839, createdTime=Tue Jun 27 00:55:47 CST 2023, time=2023-06-27, status=1, ipAttribution=湖南省)]

2023-06-27 ms6000001074362839 来自湖南省

请问大家1a状态持续了3周是为什么啊？2周前收到杂志社邮件说投稿量大，编辑初始审查延长2周，现在2周已经过了，1a一点动静也没有，是为什么呢？有一样的宝子不

246 7 举报

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务